Cellect Biotech Up 65% After Stem Cell Transplant Completed In Phase I/II Trial

Loading...
Loading...

Cellect Biotechnology Ltd APOP shares are trading higher by $4.05 (64.8 percent) at $10.31 in Monday's session.

The catalyst for the huge rally is the announcement that its first Stem Cell transplant has been completed in Phase I/II trial.

The stock, which debuted in July 2016 at $5.40, was ignored by investors and moved lower on scarce volume until it bottomed on January 31 at $2.94. It came alive in February and more than doubled from January's month-end of $3.10 to end February at $6.69. It should be noted volume really picked up in January and February as the stock bottomed and began to move higher.

After a much higher, right at its former all-time high of $8.78, Cellect's stock retreated only $0.22 before bottoming at $8.55 and resuming it move higher. So far, it has reached $13.50, but has surrendered some of those gains and is attempting to remain in double digits.

Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...